Inventiva
OrganizationHeard in 3 episodes across 1 show since Oct 2026
Inventiva is a French clinical-stage biopharmaceutical company developing oral small-molecule therapies for serious diseases with high unmet medical need. Its lead program, lanifibranor, is being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 3 |
| Nov 2026 | 0 |
Email alert
Email me when Inventiva comes up on a podcast
One email a week at most, with the new episodes that mention Inventiva. Free, no account needed, unsubscribe in one click.
What experts have said about Inventiva
19 statements · 10 positive · 7 negative · 2 neutral
Inventiva’s MASH drug Q4 readout will probably be positive.
“I think it's probably going to do well”
Open the episode · 120 - Breaking Biotech Week End Wrap Up - Oct 25th, 2026Listen at 27:16
Inventiva’s finances cap its potential upside.
“The finances of the company make it such that I think the upside is relatively capped.”
Open the episode · 119 - $IVA: Can Lanifibranor Deliver in Phase 3 MASH?Listen at 0:34
Positive phase-three data could unlock conditional financing for Inventiva.
“if the phase three data is positive”
Open the episode · 119 - $IVA: Can Lanifibranor Deliver in Phase 3 MASH?Listen at 0:44
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
3 episodes featuring Inventiva, newest first
